Guanfacine treatment for prefrontal cognitive dysfunction in older participants: a randomized clinical trial.

Guanfacine treatment for prefrontal cognitive dysfunction in older participants: a randomized clinical trial.
复制标题

鸟明治疗老年参与者的前额叶认知功能障碍:一项随机临床试验。

DOI:
10.1016/j.neurobiolaging.2018.05.033
复制
发表时间:
2018-10
影响因子:
4.2
通讯作者:
van Dyck CH
van Dyck CH
中科院分区:
医学2区
文献类型:
--
作者:
Barcelos NM;Van Ness PH;Wagner AF;MacAvoy MG;Mecca AP;Anderson GM;Trentalange M;Hawkins KA;Sano M;Arnsten AFT;van Dyck CH

文献摘要

参考文献

被引文献

相似文献

这项研究评估了α-2A型肾上腺素能受体激动剂瓜那法辛对健康老年受试者前额叶调节的认知功能以及生活质量和整体功能的影响。123名年龄在75岁及以上的受试者被随机分配,每天服用0.5 mg、0.1 mg或安慰剂,持续12周。主要的结果测量是在12周内6个前额叶执行功能任务(PEF6)的z分数的变化。与安慰剂相比,两种剂量的瓜那法辛都不能改善PEF6 z评分。12周内PEF6z评分的平均变化率[95%可信区间]安慰剂组为0.270[0.159,0.380],与之相比,瓜那法辛0.1 mg组为0.121[0.011,0.232](与安慰剂组相比,p=0.06),0.5 mg组为0.213[0.101,0.324](p=0.47)。与安慰剂相比,瓜那法辛既不能改善生活质量,也不能改善整体功能。在常见的不良事件中,与安慰剂相比,只有口干的患者使用金刚烷的频率明显更高。瓜那法辛未能改善老年人的前额叶认知功能,因为老年人的认知能力在年龄上是正常的。
This study evaluated the effect of the alpha-2A-adrenoceptor agonist guanfacine on prefrontally-mediated cognitive functions, as well as quality of life and global function in healthy older participants. One hundred twenty-three participants 75-years and older were randomly assigned to guanfacine 0.5 mg, 0.1 mg, or placebo daily for 12 weeks. The primary outcome measure was the change in z-score for 6 prefrontal executive function tasks over 12 weeks (PEF6). Neither dose of guanfacine improved PEF6 z-score relative to placebo. The rate of mean change [95% confidence interval] in PEF6 z-score over 12 weeks was 0.270 [0.159, 0.380] for placebo, compared with 0.121 [0.011, 0.232] for guanfacine 0.1 mg (p = 0.06, compared to placebo), and 0.213 [0.101, 0.324] for 0.5 mg (p = 0.47). Neither dose of guanfacine improved quality of life or global function relative to placebo. Among common adverse events, only dry mouth was significantly more frequent on guanfacine compared to placebo. Guanfacine failed to ameliorate prefrontal cognitive function in older individuals, who were cognitively normal for age.
DOI: 10.1038/nrn3200
发表时间: 2012-03-07
影响因子: 34.7
作者:
Morrison, John H.;Baxter, Mark G.
通讯作者: Baxter, Mark G.
DOI: 10.1007/s002130050533
发表时间: 1998-03-01
期刊: PSYCHOPHARMACOLOGY
影响因子: 3.4
作者:
Franowicz, JS;Arnsten, AFT
通讯作者: Arnsten, AFT
DOI: 10.1076/jcen.24.2.221.993
发表时间: 2002-01-01
影响因子: 2.2
作者:
Daigneault, G;Joly, P;Frigon, JY
通讯作者: Frigon, JY
DOI: 10.1016/s0893-133x(98)00127-4
发表时间: 1999-05-01
影响因子: 7.6
作者:
Jäkälä, P;Riekkinen, M;Riekkinen, P
通讯作者: Riekkinen, P
DOI: 10.1016/s0893-133x(98)00055-4
发表时间: 1999-02-01
影响因子: 7.6
作者:
Jäkälä, P;Sirviö, J;Riekkinen, P
通讯作者: Riekkinen, P